Advances of Targeted Therapy for Hepatocellular Carcinoma.

Front Oncol · 2021 · PMC8350567 · PMID 34381735

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase II, randomized, double-blind, placebo-controlled study, vandetanib showed a trend of improvement in PFS and OS for advanced HCC, but there was no statistically significant difference compared to the placebo arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.